RLMD

Relmada Therapeutics Inc

RLMD, USA

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

https://www.relmada.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RLMD
stock
RLMD

Relmada Therapeutics Amends Executive Employment Agreements TipRanks

Read more →
RLMD
stock
RLMD

Relmada Therapeutics updates executive contracts and increases salaries Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$5.5

Analyst Picks

Strong Buy

0

Buy

0

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

14.24

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-106.61 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-67.84 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.57

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 16.67% of the total shares of Relmada Therapeutics Inc

1.

Driehaus Capital Management LLC

(2.2295%)

since

2025/06/30

2.

BlackRock Inc

(1.5305%)

since

2025/06/30

3.

AdvisorShares Psychedelics ETF

(1.2822%)

since

2025/08/29

4.

AdvisorShares Investments, LLC

(1.1946%)

since

2025/06/30

5.

Vanguard Group Inc

(1.0969%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.9109%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.772%)

since

2025/07/31

8.

Deutsche Bank AG

(0.6774%)

since

2025/06/30

9.

CI Private Wealth LLC

(0.6226%)

since

2025/06/30

10.

UBS Group AG

(0.5437%)

since

2025/06/30

11.

Parsons Capital Management Inc

(0.4921%)

since

2025/06/30

12.

RBF LLC

(0.4919%)

since

2025/06/30

13.

Fidelity Extended Market Index

(0.4783%)

since

2025/07/31

14.

Marshall Wace Asset Management Ltd

(0.4657%)

since

2025/06/30

15.

Renaissance Technologies Corp

(0.4522%)

since

2025/06/30

16.

ADAR1 Capital Management LLC

(0.3917%)

since

2025/06/30

17.

Jane Street Group LLC

(0.3445%)

since

2025/06/30

18.

State Street Corp

(0.3216%)

since

2025/06/30

19.

We Are One Seven, LLC

(0.3013%)

since

2025/06/30

20.

Two Sigma Investments LLC

(0.2875%)

since

2025/06/30

21.

Susquehanna International Group, LLP

(0.1983%)

since

2025/06/30

22.

Northern Trust Corp

(0.1795%)

since

2025/06/30

23.

Fidelity Total Market Index

(0.1689%)

since

2025/07/31

24.

LMR Partners LLP

(0.166%)

since

2025/06/30

25.

Extended Equity Market Fund K

(0.1406%)

since

2025/06/30

26.

Fidelity Series Total Market Index

(0.1171%)

since

2025/07/31

27.

Acadian Global Small-Cap Equity CIT Cl A

(0.1092%)

since

2025/03/04

28.

NT Ext Equity Mkt Idx Fd - L

(0.1065%)

since

2025/06/30

29.

Northern Trust Extended Eq Market Idx

(0.1065%)

since

2025/06/30

30.

Spartan Extended Market Index Pool F

(0.0919%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - NL

(0.0614%)

since

2025/06/30

32.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0609%)

since

2024/12/31

33.

Spartan Total Market Index Pool G

(0.0572%)

since

2025/07/31

34.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0477%)

since

2025/06/30

35.

Blackrock US Eq Mkt Fund CF

(0.0352%)

since

2025/07/31

36.

Vanguard U.S. Eq Idx £ Acc

(0.0315%)

since

2025/07/31

37.

U.S. Equity Market Fund F

(0.0303%)

since

2025/06/30

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.03%)

since

2025/06/30

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0254%)

since

2024/12/31

40.

State St US Extended Mkt Indx NL Cl C

(0.0226%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.44

Latest Release

Date

2025-09-30

EPS Actual

-0.304

EPS Estimate

-0.45

EPS Difference

0.146

Surprise Percent

32.4444%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.